Pharmaceutical intermediates
Dapagliflozin Intermediates
7 pharmaceutical intermediates for Dapagliflozin. Indication: Chronic Renal Insufficiency; Heart Failure; Renal Disease; Type 2 Diabetes Mellitus (T2DM); Type 1 Diabetes Mellitus (T1DM).
About Dapagliflozin
- Originator
- Boehringer Ingelheim
- Indication
- Chronic Renal Insufficiency; Heart Failure; Renal Disease; Type 2 Diabetes Mellitus (T2DM); Type 1 Diabetes Mellitus (T1DM)
- Approved Date
- 10/29/2014
- DS/DP
- 10/04/2025
Available intermediates
7 intermediates currently listed for Dapagliflozin. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 5-Bromo-2-chlorobenzoic acid | 21739-92-4 | / | / |
| (5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone | 461432-22-4 | / | / |
| 4-(5-Bromo-2-chlorobenzyl)phenyl ethyl ether | 461432-23-5 | / | / |
| 1-Chloro-2-(4-ethoxybenzyl)-4-iodobenzene | 1103738-29-9 | / | / |
| 2,3,4,6-Tetrakis-0-trimethylsilyl-D-gluconolactone | 32384-65-9 | / | / |
| (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]pheny!]D-glucitol tetraacetate | 461432-25-7 | / | / |
| (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxyMethyl)-2-Methoxytetrahydro-2H-pyran-3,4,5-triol | 714269-57-5 | / | / |
我们能如何帮助您？
获取最新活动与法规动态洞察
直接发送到您的邮箱
在此获取行业洞察与 Unibest 动态
联系我们 →